Total Payments
$6,035
2024 Payments
$938.89
Companies
25
Transactions
146
Medicare Patients
7,975
Medicare Billing
$472,549
Payment Breakdown by Category
Food & Beverage$5,496 (91.1%)
Travel$486.49 (8.1%)
Education$51.97 (0.9%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,496 | 142 | 91.1% |
| Travel and Lodging | $486.49 | 1 | 8.1% |
| Education | $51.97 | 3 | 0.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Medtronic Vascular, Inc. | $825.73 | 11 | $0 (2020) |
| Janssen Pharmaceuticals, Inc | $648.14 | 12 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $563.53 | 19 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $498.29 | 15 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $439.12 | 8 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $398.95 | 9 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $347.97 | 8 | $0 (2024) |
| Merck Sharp & Dohme LLC | $330.68 | 13 | $0 (2024) |
| Boston Scientific Corporation | $321.93 | 8 | $0 (2024) |
| Amgen Inc. | $318.03 | 11 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $938.89 | 44 | Novartis Pharmaceuticals Corporation ($155.91) |
| 2023 | $811.80 | 37 | E.R. Squibb & Sons, L.L.C. ($206.12) |
| 2022 | $875.26 | 21 | Boston Scientific Corporation ($155.52) |
| 2021 | $175.05 | 3 | E.R. Squibb & Sons, L.L.C. ($105.05) |
| 2020 | $269.72 | 4 | AstraZeneca Pharmaceuticals LP ($122.93) |
| 2019 | $2,040 | 24 | Medtronic Vascular, Inc. ($679.71) |
| 2018 | $620.00 | 8 | Janssen Pharmaceuticals, Inc ($159.60) |
| 2017 | $304.08 | 5 | Gilead Sciences Inc ($99.72) |
All Payment Transactions
146 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $20.13 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/20/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $20.36 | General |
| Category: DIABETES | ||||||
| 10/30/2024 | Kestra Medical Technology Services, Inc. | Assure WCD (Device) | Food and Beverage | Cash or cash equivalent | $24.79 | General |
| Category: Cardiology | ||||||
| 10/29/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $18.04 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/10/2024 | Boston Scientific Corporation | WATCHMAN FLX (Device) | Food and Beverage | In-kind items and services | $27.28 | General |
| Category: WATCHMAN FLX_IC | ||||||
| 10/09/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $17.85 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 10/02/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $14.32 | General |
| Category: Obesity | ||||||
| 09/26/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $14.19 | General |
| Category: Cardiology | ||||||
| 09/18/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $22.31 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/11/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $17.83 | General |
| Category: DIABETES | ||||||
| 09/10/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $15.15 | General |
| Category: CARDIOVASCULAR | ||||||
| 08/29/2024 | PFIZER INC. | ELIQUIS (Drug), PAXLOVID | Food and Beverage | In-kind items and services | $22.27 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 08/15/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $20.06 | General |
| Category: Obesity | ||||||
| 07/31/2024 | CVRx, Inc. | Barostim Neo System (Device) | Food and Beverage | Cash or cash equivalent | $18.21 | General |
| Category: Heart Failure and Hypertension | ||||||
| 07/24/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $18.50 | General |
| Category: Not Applicable | ||||||
| 07/18/2024 | Boston Scientific Corporation | WATCHMAN FLX (Device) | Food and Beverage | In-kind items and services | $30.82 | General |
| Category: WATCHMAN FLX_IC | ||||||
| 07/17/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $22.16 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 06/27/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $14.72 | General |
| Category: Not Applicable | ||||||
| 06/20/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $27.96 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 06/18/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $14.06 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/12/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $23.31 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 05/28/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $18.21 | General |
| Category: CARDIOVASCULAR | ||||||
| 05/24/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $18.83 | General |
| Category: Obesity | ||||||
| 05/15/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $23.59 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 05/09/2024 | Boston Scientific Corporation | WATCHMAN FLX (Device) | Food and Beverage | In-kind items and services | $25.31 | General |
| Category: WATCHMAN FLX_IC | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 16 | 1,277 | 2,388 | $316,246 | $81,130 |
| 2022 | 20 | 1,794 | 2,956 | $423,870 | $94,154 |
| 2021 | 17 | 2,281 | 4,289 | $607,238 | $139,516 |
| 2020 | 21 | 2,623 | 5,000 | $655,435 | $157,750 |
Total Patients
7,975
Total Services
14,633
Medicare Billing
$472,549
Procedure Codes
74
All Medicare Procedures & Services
74 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 103 | 217 | $42,315 | $16,926 | 40.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 117 | 233 | $31,455 | $13,288 | 42.2% |
| 93280 | Programming of dual lead pacemaker system | Office | 2023 | 189 | 225 | $37,464 | $12,085 | 32.3% |
| 93296 | Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | Office | 2023 | 272 | 604 | $38,656 | $7,722 | 20.0% |
| 93294 | Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | Office | 2023 | 187 | 415 | $36,105 | $7,537 | 20.9% |
| 93295 | Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | Office | 2023 | 86 | 191 | $36,672 | $4,048 | 11.0% |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | Office | 2023 | 17 | 70 | $28,210 | $3,584 | 12.7% |
| 93284 | Programming of multiple lead implantable defibrillator system | Office | 2023 | 43 | 46 | $12,978 | $3,300 | 25.4% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 60 | 65 | $13,520 | $3,295 | 24.4% |
| 93283 | Programming of dual lead implantable defibrillator system | Office | 2023 | 36 | 41 | $10,086 | $2,500 | 24.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 20 | 37 | $5,550 | $2,183 | 39.3% |
| 93298 | Evaluation of cardiac rhythm monitor system, remote up to 30 days | Office | 2023 | 17 | 71 | $6,425 | $1,261 | 19.6% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 88 | 122 | $9,150 | $1,018 | 11.1% |
| 93285 | Programming of cardiac rhythm monitor system | Office | 2023 | 18 | 24 | $2,880 | $991.51 | 34.4% |
| 93282 | Programming of single lead implantable defibrillator system | Office | 2023 | 13 | 13 | $2,626 | $780.00 | 29.7% |
| 93279 | Programming of single lead pacemaker system | Office | 2023 | 11 | 14 | $2,154 | $610.90 | 28.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 99 | 204 | $39,780 | $16,024 | 40.3% |
| 93280 | Programming of dual lead pacemaker system | Office | 2022 | 240 | 281 | $47,040 | $14,194 | 30.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 122 | 199 | $26,865 | $9,987 | 37.2% |
| 93296 | Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | Office | 2022 | 395 | 763 | $70,252 | $9,405 | 13.4% |
| 93294 | Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | Office | 2022 | 262 | 507 | $51,671 | $8,385 | 16.2% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2022 | 126 | 136 | $28,288 | $6,604 | 23.3% |
| 93295 | Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | Office | 2022 | 137 | 263 | $50,496 | $5,579 | 11.0% |
| 93284 | Programming of multiple lead implantable defibrillator system | Office | 2022 | 63 | 72 | $20,646 | $4,893 | 23.7% |
| 93283 | Programming of dual lead implantable defibrillator system | Office | 2022 | 56 | 70 | $17,220 | $4,349 | 25.3% |
About Dr. Thomas Orman, MD
Dr. Thomas Orman, MD is a Cardiovascular Disease healthcare provider based in Terre Haute, Indiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/15/2006. The National Provider Identifier (NPI) number assigned to this provider is 1386618536.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Thomas Orman, MD has received a total of $6,035 in payments from pharmaceutical and medical device companies, with $938.89 received in 2024. These payments were reported across 146 transactions from 25 companies. The most common payment nature is "Food and Beverage" ($5,496).
As a Medicare-enrolled provider, Orman has provided services to 7,975 Medicare beneficiaries, totaling 14,633 services with total Medicare billing of $472,549. Data is available for 4 years (2020–2023), covering 74 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Terre Haute, IN
- Active Since 02/15/2006
- Last Updated 07/14/2014
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1386618536
Products in Payments
- XARELTO (Drug) $648.14
- Paceart (Device) $552.39
- JARDIANCE (Drug) $347.97
- ELIQUIS (Drug) $345.08
- VERQUVO (Drug) $330.68
- ENTRESTO (Drug) $319.26
- Repatha (Biological) $318.03
- FARXIGA (Drug) $283.35
- PRALUENT (Drug) $240.38
- CAMZYOS (Drug) $190.44
- LEQVIO (Drug) $179.03
- Ranexa (Drug) $170.34
- MULTAQ (Drug) $158.57
- WATCHMAN Access System (Device) $155.52
- Diamondback Coronary (Device) $146.26
- MITRACLIP (Device) $137.18
- FUROSCIX (Drug) $127.17
- Edwards SAPIEN 3 Transcatheter Heart Valve (Device) $119.75
- Medtronic External Pacemakers (Device) $103.90
- Confirm Rx (Device) $99.87
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Terre Haute
Dr. Tony Nasser, Md, MD
Cardiovascular Disease — Payments: $216,502
Cardiovascular Disease $216,502
Krishna Namburi, M.d, M.D
Cardiovascular Disease — Payments: $136,715
Cardiovascular Disease $136,715
Dr. George Bittar, Md, MD
Cardiovascular Disease — Payments: $22,879
Cardiovascular Disease $22,879
Shantilal Patel, M.d, M.D
Cardiovascular Disease — Payments: $15,053
Cardiovascular Disease $15,053
Dr. Neil Kabous, Md, MD
Cardiovascular Disease — Payments: $13,262
Cardiovascular Disease $13,262
John Yacoub, Md, MD
Cardiovascular Disease — Payments: $12,540
Cardiovascular Disease $12,540